LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin alpha3beta1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer[1][2].
Molekulargewicht:
885.88
CAS Nummer:
[1095009-44-1]
Formel:
C32H43N11O15S2
Target-Kategorie:
Integrin
Anwendungsbeschreibung:
MCE Product type: Peptides
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
